The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1560-1565

  Kuenen Boumeester, V ^a   Van Der Kwast, T H ^b   Claassen, C C ^a   Look, M P ^a   Liem, G S ^a   Klijn, J G M ^a   Henzen Logmans, S C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Androgen receptor; Breast cancer; Immunohistochemistry; Multivariate analysis; Prognosis

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0008398439     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00112-8     Document Type: Article

References (31)

1. 1. Simpson JF, Page DL. Prognostic value of histopathology in the breast. Semin Oncol 1992, 19, 254-262.
2. 2. Dixon JM, Page DL, Anderson TJ, et al. Long-time survivors after breast cancer. Br J Surg 1985, 72, 445-448.
3. 3. Fisher ER, Redmond C, Fisher B, Bass G. Pathologic findings from the national surgical adjuvant breast and bowel projects (NSABP). Cancer 1990, 65, 2121-2128.
4. 4. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992, 20, 479-489.
5. 5. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995, 27, 219-226.
6. 6. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983, 52, 1551-1557.
7. 7. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980, 15, 239-251.
8. 8. Clark GM, Sledge GW, Kent Osborne C, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987, 4, 55-61.
9. 9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19, 403-410.
10. 10. McGurrin JF, Doria MI, Dawson PJ, Karrison Th, Stein HO, Franklin WA. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 1987, 59, 1744-1750.
11. 11. Tubiana M, Pejovic MH, Chavandra N, Contessa G, Malaise EP. The longterm prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 1984, 33, 441-445.
12. 12. Meyer JS, Bauer WC, Rao BR. Subpopulations of breast carcinoma defined by S-phase fraction, morphology and estrogen receptor content. Lab Invest 1978, 39, 225-235.
13. 13. Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer. Acta Oncol 1988, 27, 1-18.
14. 14. Foekens JA, Portengen H, Van Putten WLJ, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989, 49, 5823-5828.
15. 15. Kuenen-Boemeester V, Van Der Kwast ThH, Van Laarhoven HAJ, Henzen-Logmans SC. Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. J Clin Pathol 1991, 44, 208-210.
16. 16. Kuenen-Boumeester V, Van Der Kwast ThH, Van Putten WLJ, Claassen C, Van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer 1992, 52, 581-584.
17. 17. Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 1983, 98, 139-144.
18. 18. Ingle JN, Twito DI, Schaid DJ, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. Cancer 1991, 67, 886-891.
19. 19. Page DL, Anderson TJ. Diagnostic Histopathology of the Breast. New York, Churchill Livingstone, 1987, Chapter 17, 303-307.
20. 20. World Health Organisation. International Histological Classification of Tumours., No. 2, Histological Typing or Breast Tumours, 2nd edn. Geneva, World Health Organisation, 1981.
21. 21. Zegers ND, Claassen E, Neelen C, et al. Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta 1991, 1073, 23-32.
22. 22. Henzen-Logmans SC, Fieret EJH, Berns EMJJ, Van Der Burg MEL, Klijn JGM, Foekens JA. Ki-67 staining in benign, border-line, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D. Int J Cancer 1994, 57, 468-472.
23. 23. Heubner A, Beck T, Grill HJ, Follow K. Comparison of immunocytochemical estrogen receptor assay, estrogen receptor enzyme immunoassay, and radioligand-labeled estrogen receptor assay in human breast cancer and uterine tissue. Cancer Res 1986, 46 (Suppl), 4291s-4295s.
24. 24. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, Van der Kwast ThH. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991, 39, 927-936.
25. 25. Helin HJ, Helle MJ, Kallioniemi O, Isola JJ. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Cancer 1989, 63, 1761-1767.
26. 26. Di Stefano D, Mingazzini PI, Scucchi L, Donnetti M, Marinozzi V. A comparative study of histopathology, hormone receptors, peanut lectine binding, Ki-67 immunostaining and nucleolar organizer region associated proteins in human breast cancer. Cancer 1991, 67, 463-467.
27. 27. Wintzer HO, Zipfel I, Schulte-Mönting J, Hellerich U, Von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991, 67, 421-428.
28. 28. Gasparini G, Dal Fior S, Pozza F, Bevilacqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat 1989, 14, 329-336.
29. 29. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993, 170, 31-35.
30. 30. Teulings FAG, Van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J. Estrogen, androgen, glucocorticoid and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 1980, 40, 2557-2561.
31. 31. Hackenberg R, Hawighorst T, Filmer A, Huschmand Nia A, Schulz K. Medoxyprogesterone acetate inhibits the proliferation of estrogen-and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat 1993, 25, 217-224.